

Kakuhiro Yamaguchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6758144/publications.pdf>

Version: 2024-02-01

61
papers

542
citations

759055

12
h-index

752573

20
g-index

62
all docs

62
docs citations

62
times ranked

733
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. <i>Respiratory Investigation</i> , 2019, 57, 451-459.	0.9	76
2	Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. <i>Lung Cancer</i> , 2018, 119, 21-24.	0.9	34
3	Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers. <i>JAMA Network Open</i> , 2020, 3, e2022906.	2.8	32
4	Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis. <i>Respirology</i> , 2020, 25, 275-280.	1.3	30
5	<i>AGER</i> gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis. <i>Respirology</i> , 2017, 22, 965-971.	1.3	28
6	Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. <i>BMC Medical Genetics</i> , 2017, 18, 88.	2.1	26
7	Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 74-81.	1.0	25
8	Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2984-2994.	1.6	23
9	High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery. <i>Medicine (United States)</i> , 2019, 98, e14296.	0.4	21
10	Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1. <i>Cancer Letters</i> , 2019, 442, 31-39.	3.2	15
11	Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress. <i>Free Radical Biology and Medicine</i> , 2019, 136, 52-59.	1.3	14
12	C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis. <i>Respiration</i> , 2019, 98, 212-220.	1.2	13
13	Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 5725-5731.	0.5	13
14	Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2020, 21, 145.	1.4	13
15	Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis. <i>Respiratory Investigation</i> , 2020, 58, 465-472.	0.9	11
16	IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis. <i>PLoS ONE</i> , 2021, 16, e0252594.	1.1	11
17	Accelerated decline in lung function in adults with a history of remitted childhood asthma. <i>European Respiratory Journal</i> , 2022, 59, 2100305.	3.1	9
18	<i>AGER</i> rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 94382-94392.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients. <i>Internal Medicine</i> , 2019, 58, 915-920.	0.3	7
20	Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma. <i>Internal Medicine</i> , 2021, 60, 611-615.	0.3	7
21	Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis. <i>Stem Cell Research and Therapy</i> , 2021, 12, 506.	2.4	7
22	Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report. <i>Journal of Asthma</i> , 2022, 59, 2395-2401.	0.9	7
23	Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis. <i>Internal Medicine</i> , 2019, 58, 3129-3132.	0.3	6
24	Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease. <i>Respiratory Medicine</i> , 2020, 172, 106131.	1.3	6
25	A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). <i>Clinical Lung Cancer</i> , 2021, 22, 276-289.	1.1	6
26	Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports. <i>Thoracic Cancer</i> , 2021, 12, 2956-2960.	0.8	6
27	Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation. <i>Respiratory Investigation</i> , 2022, , .	0.9	6
28	Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. <i>In Vivo</i> , 2018, 32, 1155-1160.	0.6	5
29	Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1079-1084.	0.6	5
30	Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma. <i>Clinical Respiratory Journal</i> , 2021, 15, 48-55.	0.6	5
31	Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 10105.	1.6	5
32	Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone. <i>Anticancer Research</i> , 2021, 41, 2661-2667.	0.5	5
33	Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia. <i>Respiratory Medicine</i> , 2019, 152, 44-50.	1.3	4
34	Rapid changes of nailfold capillary abnormalities during treatment for a patient with dermatomyositis complicated by lung cancer: a case report. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 95-100.	0.3	4
35	Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 857-865.	1.1	4
36	Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity. <i>Stem Cell Research and Therapy</i> , 2021, 12, 471.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small cell lung cancer expressing high PD-L1. <i>Thoracic Cancer</i> , 2022, 13, 1611-1618.	0.8	4
38	Alternate-day administration of S ¹ for elderly patients with advanced non-small cell lung carcinoma: A prospective feasibility study. <i>Molecular and Clinical Oncology</i> , 2018, 9, 539-544.	0.4	3
39	Coexisting TIF1 ³ -positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 ³ Antibody-positive Dermatomyositis. <i>Internal Medicine</i> , 2020, 59, 2553-2558.	0.3	3
40	Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization. <i>Medicine (United States)</i> , 2020, 99, e18694.	0.4	3
41	Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 369-379.	1.7	3
42	Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for <i>Pneumocystis pneumonia</i> : A retrospective cohort study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 67, 101999.	1.1	3
43	First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations. <i>Thoracic Cancer</i> , 2022, 13, 771-774.	0.8	3
44	Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis. <i>Internal Medicine</i> , 2022, 61, 2961-2965.	0.3	3
45	Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 1497-1506.	0.5	2
46	Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis. <i>American Journal of Clinical Pathology</i> , 2021, 156, 644-652.	0.4	2
47	Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1617-1623.	0.7	2
48	Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4. <i>Internal Medicine</i> , 2022, 61, 1043-1048.	0.3	2
49	Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2022, 14, 1454-1459.	0.3	2
50	A Case of Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General Anesthesia. <i>Internal Medicine</i> , 2021, , .	0.3	1
51	Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case report. <i>Journal of Asthma</i> , 2021, , 1-5.	0.9	1
52	Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 298.	1.2	1
53	Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15171-e15171.	0.8	1
54	Two Cases of Cranial Nerve Metastasis Treated with Radiotherapy and Chemotherapy in Patients with Lung Adenocarcinoma. <i>Case Reports in Oncology</i> , 2021, 13, 1495-1500.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.. Journal of Clinical Oncology, 2022, 40, e21156-e21156.	0.8	1
56	Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 871-877.	1.3	0
57	Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report. Clinical Journal of Gastroenterology, 2021, 14, 484-488.	0.4	0
58	A Case of Asian Variant Intravascular Large B-cell Lymphoma Diagnosed Based on a Thoracoscopic Lung Biopsy That Exhibited Remission and Exacerbation on Computed Tomography. Japanese Journal of Lung Cancer, 2013, 53, 99-103.	0.0	0
59	EGFR gene mutation is not a significant prognostic factor in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone.. Journal of Clinical Oncology, 2020, 38, e21736-e21736.	0.8	0
60	Clinical significance of BIM-deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e21536-e21536.	0.8	0
61	Validity and Reliability of the Japanese Version of the Dyspnea-12 Questionnaire in Patients with Lung Cancer. Journal of Pain and Symptom Management, 2022, , .	0.6	0